These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 18543809)
21. The why, what, and how of management innovation. Hamel G Harv Bus Rev; 2006 Feb; 84(2):72-84, 163. PubMed ID: 16485806 [TBL] [Abstract][Full Text] [Related]
22. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Federsel HJ Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405 [TBL] [Abstract][Full Text] [Related]
23. How CEOs manage growth agendas. Freeman KW; Nolen G; Tyson J; Lewis KD; Greifeld R; Gulati R Harv Bus Rev; 2004; 82(7-8):124-32, 189. PubMed ID: 15241959 [TBL] [Abstract][Full Text] [Related]
24. Research and development productivity map: visualization of industry status. Shimura H; Masuda S; Kimura H J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433 [TBL] [Abstract][Full Text] [Related]
25. Partnership between small biotech and big pharma. Wiederrecht GJ; Hill RG; Beer MS IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465 [TBL] [Abstract][Full Text] [Related]
26. Conducting pharmaceutical R&D in India - Critical components of entry strategies. Gulati R IDrugs; 2008 Nov; 11(11):817-22. PubMed ID: 18988126 [TBL] [Abstract][Full Text] [Related]
28. Can science be a business? Lessons from biotech. Pisano GP Harv Bus Rev; 2006 Oct; 84(10):114-24, 150. PubMed ID: 17040044 [TBL] [Abstract][Full Text] [Related]
29. How we're fixing up Tyco. Pillmore EM Harv Bus Rev; 2003 Dec; 81(12):96-103, 126. PubMed ID: 14712548 [TBL] [Abstract][Full Text] [Related]
30. Effective executive management in the pharmaceutical industry. Tran H; Kleiner BH J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973 [TBL] [Abstract][Full Text] [Related]
31. Solve the succession crisis by growing inside-outside leaders. Bower JL Harv Bus Rev; 2007 Nov; 85(11):90-6, 153. PubMed ID: 18159789 [TBL] [Abstract][Full Text] [Related]
32. Funding growth in an age of austerity. Hamel G; Getz G Harv Bus Rev; 2004; 82(7-8):76-84, 186. PubMed ID: 15241954 [TBL] [Abstract][Full Text] [Related]
35. Leading change from the top line. Interview by Thomas A Stewart and David Champion. Hassan F Harv Bus Rev; 2006; 84(7-8):90-7, 188. PubMed ID: 16846192 [TBL] [Abstract][Full Text] [Related]
36. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
37. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Danzon PM; Nicholson S; Pereira NS J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048 [TBL] [Abstract][Full Text] [Related]
38. The state of innovation in drug development. Kola I Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690 [TBL] [Abstract][Full Text] [Related]
39. Not all M&As are alike--and that matters. Bower JL Harv Bus Rev; 2001 Mar; 79(3):92-101, 164. PubMed ID: 11246927 [TBL] [Abstract][Full Text] [Related]